

REMARKS

The Examiner rejected claim 15. Claim 15 has been amended herein to recite that the administration is an extracranial administration. In addition, claims 16-26 have been added herein. Thus, claims 15-26 are pending.

Applicants' specification fully supports these amendments. For example, the section extending from page 16, line 25 to page 17, line 8 discloses extracranially administering PNA oligomers, while page 16, lines 8-16 disclose carrier-free PNA oligomers. See, also, original claims 3-6. Thus, no new matter has been added.

In light of the following remarks, Applicants respectfully request reconsideration and allowance of claims 15-26.

Double Patenting

The Examiner rejected claim 15 under the judicially-created doctrine of obviousness-type double patenting as being allegedly unpatentable over claims 1-52 of U.S. Patent No. 6,472,209 and claims 1-4 of U.S. Patent No. 6,723,560 B2. Two terminal disclaimers have been filed herewith obviating the these obviousness-type double patenting rejections. Thus, these rejections are moot.

Applicant : Elliott Richelson et al.
Serial No. : 10/799,238
Filed : March 12, 2004
Page : 5 of 5

Attorney's Docket No.: 07039-126002 / MMV-97-105


CONCLUSION

Applicants respectfully assert that claims 15-26 are in condition for allowance, which action is requested. The Examiner is invited to telephone the undersigned if such would expedite prosecution.

Please apply any charges or credits to deposit account 06-1050.

Respectfully submitted,

Date: April 17, 2006



J. Patrick Finn III, Ph.D.
Reg. No. 44,109

Fish & Richardson P.C.
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696